Applies to the following strength(s): 30 mg ; 90 mg ; 60 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Chronic Hepatitis C
60 mg orally once a day for 12 weeks
-Sustained virologic response rates reduced in HCV genotype 3-infected patients with cirrhosis using this drug with sofosbuvir for 12 weeks; optimal duration of therapy has not been established for patients with cirrhosis.
-The manufacturer product information for sofosbuvir should be consulted.
Use: In combination with sofosbuvir, for the treatment of patients with chronic HCV genotype 3 infection
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
Mild, moderate, or severe liver dysfunction (Child-Pugh A, B, or C): No adjustment recommended.
Decompensated cirrhosis: Data not available
Coadministration with strong CYP450 3A inhibitors: Dose should be reduced to 30 mg orally once a day.
Coadministration with moderate CYP450 3A inducers: Dose should be increased to 90 mg orally once a day.
Coadministration with strong CYP450 3A inducers: Contraindicated
The dose of this drug should not be reduced for side effects.
If sofosbuvir is permanently discontinued, this drug should also be discontinued.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Any degree of renal dysfunction: No adjustment recommended.
Comments: This drug is highly protein-bound; significant removal via dialysis is not likely.
-Use in combination with sofosbuvir; do not use alone.
-May take without regard to food
-Consult the manufacturer product information regarding missed doses.
-Before starting therapy, the manufacturer product information for coadministered drugs should be consulted for additional information.
More about daclatasvir
- Other brands: Daklinza